1597 related articles for article (PubMed ID: 10784622)
21. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
22. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
24. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
[TBL] [Abstract][Full Text] [Related]
25. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.
Watts MJ; Sullivan AM; Jamieson E; Pearce R; Fielding A; Devereux S; Goldstone AH; Linch DC
J Clin Oncol; 1997 Feb; 15(2):535-46. PubMed ID: 9053475
[TBL] [Abstract][Full Text] [Related]
26. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R
J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013
[TBL] [Abstract][Full Text] [Related]
27. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
29. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
30. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
[TBL] [Abstract][Full Text] [Related]
31. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.
Akard LP; Thompson JM; Dugan MJ; Wiemann M; Greenspan A; Hanks S; Swinney M; Nyhuis A; Jansen J
Biol Blood Marrow Transplant; 1999; 5(6):379-85. PubMed ID: 10595815
[TBL] [Abstract][Full Text] [Related]
32. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
[TBL] [Abstract][Full Text] [Related]
33. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
35. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
[TBL] [Abstract][Full Text] [Related]
40. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J
Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
